Parabilis Medicines Presents Clinical Data Demonstrating First-Ever Drugging of Key Cancer Driver with FOG-001
Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced at the ESMO Congress 2025 the first-ever clinical data showing that its investigational FOG-001 therapy has successfully drugged β-catenin:TCF – a key cancer-driving node in the Wnt/β-catenin pathway, until now considered “undruggable.”
Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced the appointment of Fawzi Benzaghou, M.D., as the company’s Chief Medical Officer. Dr. Benzaghou is a seasoned and highly successful oncology leader with deep industry and regulatory experience spanning all stages of global drug development, from early-stage discovery and clinical development through regulatory approval and commercialization.
Parabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Medical Meetings
Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced the presentations of trial-in-progress posters on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-cateninTCF4, at the ASCO Annual Meeting, which begins on May 30 in Chicago, Illinois, and the ESMO Gastrointestinal Cancers Congress 2025, which begins on July 2 in Barcelona, Spain.
Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, is presenting preclinical data demonstrating first-in-industry targeted degradation of ERG at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which begins today in Chicago, Illinois.
Parabilis Medicines to Present First Preclinical Data on ERG Degrader Program at AACR Annual Meeting
Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced the presentation of preclinical data on its first-in-class targeted protein degrader of ERG at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 25–30, 2025, in Chicago, Illinois.
Parabilis Medicines to Present Trial-in-Progress Poster on Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at ASCO Gastrointestinal Cancers Symposium
Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer, today announced the presentation of a trial-in-progress poster on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-cateninTCF4, at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco from January 23-25, 2025.
Parabilis Medicines Presents Updates on Clinical Progress of β-cateninTCF4 Inhibitor, Helicon™ Portfolio and Discovery Engine at J.P. Morgan Healthcare Conference
Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer, today presented updates from its targeted first-in-class oncology programs at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
Parabilis Medicines™ (formerly FogPharma), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer, today announced a corporate name change. The company’s new name, Parabilis (pronounced puh-RAH-buh-liss), draws on Greek and Latin etymologies to mean both ‘beyond what’s possible’ and ‘obtainable,’ reflecting the company’s drive to expand what is therapeutically possible for the treatment of serious diseases, and its commitment to ensuring its medicines reach and benefit patients globally.
